Roche to acquire liver drug developer 89bio for up to $3.5 billion

Core Viewpoint - Roche has agreed to acquire U.S. biotech firm 89bio for up to $3.5 billion to enhance its development pipeline focused on liver and cardiometabolic disease treatments [1] Company Summary - The acquisition amount is up to $3.5 billion, indicating Roche's commitment to expanding its portfolio in the biotech sector [1] - The target company, 89bio, specializes in treatments for liver and cardiometabolic diseases, aligning with Roche's strategic focus [1] Industry Summary - This acquisition reflects a growing trend in the biotech industry where larger firms are seeking to bolster their pipelines through strategic acquisitions [1] - The focus on liver and cardiometabolic diseases highlights the increasing importance of these areas in the healthcare market [1]